Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension
暂无分享,去创建一个
N. Smedira | R. Dweik | Xiaofeng Wang | J. DiDonato | G. Heresi | G. Khirfan | V. Tejwani | Manshi Li
[1] G. Kopeć,et al. HDL Cholesterol as a Marker of Disease Severity and Prognosis in Patients with Pulmonary Arterial Hypertension , 2019, International journal of molecular sciences.
[2] Yunxia Zhang,et al. Circulating biomarkers in chronic thromboembolic pulmonary hypertension , 2019, Pulmonary circulation.
[3] A. Makino,et al. Pulmonary vascular dysfunction in metabolic syndrome , 2018, The Journal of physiology.
[4] H. Ghofrani,et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension , 2017, European Respiratory Review.
[5] R. Dweik,et al. Abnormal Glucose Metabolism and High‐Energy Expenditure in Idiopathic Pulmonary Arterial Hypertension , 2017, Annals of the American Thoracic Society.
[6] P. Dorfmüller,et al. The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. , 2016, Annals of the American Thoracic Society.
[7] S. Kushwaha,et al. Usefulness of High-Density Lipoprotein Cholesterol to Predict Survival in Pulmonary Arterial Hypertension. , 2016, The American journal of cardiology.
[8] W. Seeger,et al. The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension , 2016, PloS one.
[9] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.
[10] Simon Gibbs,et al. [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.
[11] Victor Mor-Avi,et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[12] M. Madani,et al. Chronic thromboembolic pulmonary hypertension. , 2014, The Lancet. Respiratory medicine.
[13] E. Michelakis,et al. The Metabolic Theory of Pulmonary Arterial Hypertension , 2014, Circulation research.
[14] M. Humbert,et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. , 2014, Circulation research.
[15] W. Seeger,et al. Algorithm of Pulmonary Arterial Hypertension , 2022 .
[16] W. Klepetko,et al. Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy , 2013, Thorax.
[17] M. Humbert,et al. Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[18] Horst Olschewski,et al. Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[19] W. Seeger,et al. HbA1c in pulmonary arterial hypertension: a marker of prognostic relevance? , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[20] Z. Jing,et al. Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. , 2012, The American journal of cardiology.
[21] M. Madani,et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. , 2012, The Annals of thoracic surgery.
[22] Y. E. Chen,et al. Human apolipoprotein A-I induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through ATP-binding cassette transporter A1. , 2011, American journal of physiology. Cell physiology.
[23] W. Klepetko,et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. , 2011, The Journal of thoracic and cardiovascular surgery.
[24] T. Rice,et al. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[25] R. Dweik,et al. Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.
[26] H. Vliegen,et al. Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism , 2010, Haematologica.
[27] G. Hansmann,et al. Insulin resistance in pulmonary arterial hypertension , 2008, European Respiratory Journal.
[28] P. Corris,et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.
[29] M. Olschewski,et al. Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension , 2008, European Respiratory Journal.
[30] J. Pepke-Żaba,et al. Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. , 2007, Respiratory medicine.
[31] Ahmad Y. Sheikh,et al. Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator–Activated Receptor-&ggr; Activation , 2007 .
[32] Paolo Prandoni,et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.
[33] Shirin Rahmani,et al. Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment , 2003, Circulation.
[34] G. Franceschini,et al. Endothelial Protection by High-Density Lipoproteins: From Bench to Bedside , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[35] P. Shaul. Regulation of endothelial nitric oxide synthase: location, location, location. , 2002, Annual review of physiology.
[36] Richard G. W. Anderson,et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.
[37] A. von Eckardstein,et al. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[38] J. Viikari,et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. , 1999, Atherosclerosis.
[39] José A Fernández,et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. , 1999, The Journal of clinical investigation.
[40] H. Sinzinger,et al. Hyperalphalipoproteinemia and prostaglandin I2 stability. , 1997, Thrombosis research.
[41] A Giaid,et al. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.
[42] R. Epand,et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[43] K. Moser,et al. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. , 1993, Chest.
[44] B. Groves,et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.
[45] E. Mohler,et al. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. , 1991, The American journal of cardiology.
[46] T. Aoyama,et al. Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. , 1990, Circulation.
[47] C Kawai,et al. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. , 1988, The Journal of clinical investigation.